Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SAVA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

10/23/2021 | 06:01pm EST

The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors of Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava”) of upcoming deadline in securities fraud class action lawsuit filed on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”).

CLICK HERE TO SUBMIT YOUR CASSAVA LOSSES

LEAD PLAINTIFF DEADLINE: October 26, 2021

CLASS PERIOD: September 14, 2020 through August 27, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Toll Free (844) 887-9500 or Email at info@ktmc.com

CASSAVA’S ALLEGED MISCONDUCT

Cassava is a clinical stage biotechnology company. Its lead therapeutic product candidate is called simufilam (formerly PTI-125) developed as a treatment for Alzheimer’s disease. Simufilam purportedly targets an altered form of a protein called filamin A (“FLNA”) in the Alzheimer’s brain and reverts it to its native, healthy conformation, thereby countering the downstream toxic effects of altered FLNA.

The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) data underlying the foundational research for Cassava’s product candidates had been manipulated; (2) experiments using post-mortem human brain tissue frozen for nearly 10 years was contrary to a basic understanding of neurobiology; (3) biomarker analysis for patients treated with simufilam had been manipulated to conclude that simufilam was effective; (4) Quanterix Corp., an independent company, had not interpreted the test results or prepared the data charts for the biomarker analysis for patients treated with simufilam; (5) as a result of the foregoing, there was a reasonable likelihood that Cassava would face regulatory scrutiny in connection with the development of simufilam; and (6) as a result of the foregoing, the defendants’ positive statements about Cassava’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT CAN I DO?

Cassava investors may, no later than October 26, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer& Check, LLP encourages Hyzon investors who have suffered significant losses to contact the firm directly to acquire more information.

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Because Kessler Topaz Meltzer & Check, LLP prosecutes class actions on a contingency fee basis, there are no out-of-pocket fees or expenses paid by the lead plaintiff, regardless of the outcome of the case. If we are successful in obtaining a recovery for the class, we will apply to the court for a fee that fairly represents the work performed and risk assumed. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

CLICK HERE TO SIGN UP FOR THE CASE

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. At the end of the day, we have succeeded if the bad guys pay up, and if you recover your assets. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.


ę Business Wire 2021
All news about CASSAVA SCIENCES, INC.
12/03CORRECTING AND REPLACING CASSAVA SCI : Bragar Eagel & Squire, P.C. Is Investigating Cassav..
BU
11/19CASSAVA SCIENCES : Corporate Presentation – November 2021
PU
11/18Cassava Sciences Starts Second Phase 3 Trial of Investigational Therapy for Alzheimer's..
MT
11/18Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Pat..
AQ
11/18Cassava Sciences Initiates Second Phase 3 Study of Simufilam for the Treatment of Patie..
CI
11/17Cassava Sciences Shares Slump After Report of SEC Probe Into Research Manipulation Clai..
MT
11/17--STREET COLOR : SEC Investigating Whether Cassava Sciences Manipulated Results of Alzheim..
MT
11/17SEC INVESTIGATING CASSAVA SCIENCES : Dj
MT
11/15CASSAVA SCIENCES INC Management's Discussion and Analysis of Financial Condition and R..
AQ
11/10Cassava Sciences Widens Net Loss in Q3; Shares Down Pre-Bell
MT
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -61,5x
Yield 2021 -
Capitalization 2 000 M 2 000 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 30,0x
Nbr of Employees 11
Free-Float 93,6%
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 49,98 $
Average target price 140,67 $
Spread / Average Target 181%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.632.84%2 000
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531